RALEIGH, N.C., Sept. 26, 2017 -- Cohera Medical, Inc. ®, a medical device company that completed their relocation to the triangle area earlier this year, announced their selection as a finalist for the NC Tech Awards Innovative Product award. The NC Tech Awards is North Carolina's only statewide technology awards program that recognizes for achievement in technology and is presented by the North Carolina Technology Association (NCTA).
Cohera Medical, Inc., is commercializing a revolutionary line of surgical adhesives and sealants. Their products are based on unique chemical designs that are purely synthetic, easy to use, biocompatible and resorbable. The company has two product lines built on their game changing chemical platform. Their first product, TissuGlu Surgical Adhesive is the first ever internal surgical adhesive, and was designed to help surgeons eliminate the need for post-surgical drains for many patients. TissuGlu is approved for sale in the U.S. and EU markets. The company’s second product, Sylys® Surgical Sealant, was designed to help reduce leakage in gastrointestinal procedures and is currently under clinical investigation in the U.S. and Europe. Sylys will be a breakthrough in this procedural market that will lead to improved patient outcomes as well as reduced healthcare costs for providers.
“It is an honor to be recognized by NCTA for Cohera Medical Inc.’s commitment to innovation and improving patient care,” said Patrick Daly, President and CEO of Cohera Medical, Inc. “It is a testament to the continual hard work and dedication of our team and we are excited join North Carolina’s thriving tech industry.”
“For over 20 years, the NC Technology Association has celebrated companies, organizations and individuals for outstanding achievement at the NC Tech Awards. As a finalist this year, Cohera Medical, Inc. has distinguished itself as one of the state’s innovative and emergent leaders,” stated Brooks Raiford, NCTA’s President and CEO.
The awards process culminates with the NC Tech Awards Gala on November 9, 2017 at the Sheraton Imperial Hotel & Convention Center in Durham where hundreds of business, technology and public leaders from across the state will gather to celebrate the tech sector and honor the winners and finalists in each category.
MEDIA CONTACTS
Cohera Medical, Inc.
Lindsay Koren
Sr. Marketing Manager
[email protected]
(984) 222-0400 (office)
MedThink Communications
Alison Puzia
Senior Account Executive
[email protected]
(919) 926-3628 (office)
NCTA Media Contact:
Rachel Kennedy
NCTA Communications
[email protected]
919.856.0393
About NCTA
The North Carolina Technology Association (NCTA) is a not-for-profit, membership-driven trade association and the primary voice of the technology industry in North Carolina. NCTA is the intersection of leadership and technology, fueling the growth of North Carolina through Executive Engagement, Public Affairs, and a Knowledge Workforce. For more information, visit our website at www.nctechnology.org.
About Cohera Medical
Cohera Medical, Inc. is a growing medical device company that is developing and commercializing a line of surgical adhesives and sealants. Cohera Medical’s products are based on a unique chemical design that is resorbable, non-toxic, and easy-to-use. The Company’s lead product, TissuGlu Surgical Adhesive, is indicated for use in the U.S. for the approximation of tissue planes in abdominoplasty procedures. Refer to the complete Directions for Use information available at TissuGlu.com for a full description of use information including the contraindications, warnings, precautions, benefits, and risks of use of TissuGlu Surgical Adhesive. TissuGlu is currently approved for sale in the EU for the approximation of tissue layers where subcutaneous dead space exists between the tissue planes in large flap surgical procedures such as abdominoplasty and is being utilized in Europe to eliminate drains or reduce complications in patients undergoing large flap surgical procedures such as abdominoplasty, mastectomy, ventral hernia repair, decubitus and latissimus dorsi flap procedures. The Company’s second product under development, Sylys® Surgical Sealant, the first synthetic sealant designed specifically to help reduce anastomotic leaks, has received CE Mark approval in Europe as an adjunct to standard closure in ileostomy reversal procedures. TissuGlu and Sylys are the first products in a pipeline of technology that includes adhesives for surgical mesh fixation, meniscal repair and other orthopedic indications. Sylys and the other Cohera Medical products are currently available for investigational use only and have not yet been approved for sale by the Food and Drug Administration (FDA) in the U.S.
Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company’s future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.
©2017 Cohera Medical, Inc. All Rights Reserved. Cohera Medical, Inc.®, TissuGlu®, and Sylys® are registered trademarks of Cohera Medical, Inc.
TissuGlu® Surgical Adhesive is covered by one or more of the following U.S. Patents 7,264,823; 8,182,647; 8,652,293; 8,950,629. Other Patents Pending.


Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S.
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 



